Health · 19 views
CRISPR gene-editing therapy safely and continuously lowers cholesterol and triglycerides, first-in-human trial shows
A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL ("bad") cholesterol and triglycerides in people with…
Summary
A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL ("bad") cholesterol and triglycerides in people with medication-resistant lipid disorders through one year of follow-up across all doses. The Phase I trial, which included 15 patients, aimed to see if the reductions in LDL cholesterol and triglycerides previously reported after two months would persist for 12 months.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- New model tracks vocal fold fatigue as it develops, study showsContinue reading
- Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastasesContinue reading
- Recommendations updated for management of anemia in chronic kidney diseaseContinue reading
- First dual-target high-intensity focused ultrasound procedure for people with advanced Parkinson's diseaseContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow